525 related articles for article (PubMed ID: 33866190)
1. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Kuwano H
Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
[TBL] [Abstract][Full Text] [Related]
4. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
[TBL] [Abstract][Full Text] [Related]
5. Discordant results in
Parisse-Di Martino S; Faure C; Mognetti T
Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
8. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
9. FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients.
Borm KJ; Voppichler J; Düsberg M; Oechsner M; Vag T; Weber W; Combs SE; Duma MN
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):574-582. PubMed ID: 30118822
[TBL] [Abstract][Full Text] [Related]
10. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Cermik TF; Mavi A; Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
[TBL] [Abstract][Full Text] [Related]
12. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
[TBL] [Abstract][Full Text] [Related]
14. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
[TBL] [Abstract][Full Text] [Related]
15. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
[No Abstract] [Full Text] [Related]
16. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis.
Jung NY; Kim SH; Kang BJ; Park SY; Chung MH
Breast Cancer; 2016 Sep; 23(5):712-7. PubMed ID: 26219608
[TBL] [Abstract][Full Text] [Related]
17. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
[TBL] [Abstract][Full Text] [Related]
18. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
20. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
